Cargando…
Management of the Adult with Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH), most commonly due to 21-hydroxylase deficiency (21OHD), has been studied by pediatric endocrinologists for decades. Advances in the care of these patients have enabled many of these children to reach adulthood. In contrast to the course and management of the dis...
Autor principal: | Auchus, Richard J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896848/ https://www.ncbi.nlm.nih.gov/pubmed/20613954 http://dx.doi.org/10.1155/2010/614107 |
Ejemplares similares
-
Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia
por: Prete, Alessandro, et al.
Publicado: (2021) -
MON-183 Adrenal Androgen Control and Steroidal Side Effects in Adolescents and Adults with Congenital Adrenal Hyperplasia Treated with Glucocorticoids
por: Falhammar, Henrik, et al.
Publicado: (2020) -
Congenital adrenal hyperplasia
por: Dessinioti, Cleo, et al.
Publicado: (2009) -
Congenital Adrenal Hyperplasia
por: Speiser, Phyllis W.
Publicado: (2015) -
Pregnancy and Prenatal Management of Congenital Adrenal Hyperplasia
por: Cera, Gianluca, et al.
Publicado: (2022)